Anthelmintic Drugs Market Report 2024

This Anthelmintic Drugs market report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The anthelmintic drugs market size has grown strongly in recent years. It will grow from $3.0 billion in 2023 to $3.16 billion in 2024 at a compound annual growth rate (CAGR) of 5.3%. The growth during the historic period can be attributed to several factors such as the high prevalence of helminth infections, increased public health initiatives, rising pharmaceutical research and development, greater awareness and education, and overall economic growth.

The anthelmintic drugs market size is expected to see strong growth in the next few years. It will grow to $3.9 billion in 2028 at a compound annual growth rate (CAGR) of 5.4%. The growth during the forecast period can be attributed to several factors such as the rising incidence of parasitic infections worldwide, increased use of anthelmintics in livestock and pets, growing awareness and health initiatives, and more frequent international travel. Key trends expected during this period include a rising demand for combination therapies, a heightened focus on managing drug resistance, growing adoption of personalized medicine, expansion of telemedicine for treatment monitoring, increased research on novel drug targets, and an emphasis on preventive healthcare measures.

The high prevalence of parasitic infections is anticipated to drive the growth of the anthelmintic drugs market in the future. Parasitic infections are diseases caused by organisms that live on or inside a host, such as protozoa, worms, or ectoparasites. These infections are exacerbated by factors such as poor sanitation, contaminated food or water, close contact with infected individuals or animals, inadequate hygiene, and lack of access to clean resources. Anthelmintic drugs are used to treat infections caused by parasitic worms by targeting and eliminating these parasites from the host's body. These medications disrupt the physiological functions of the parasites, leading to their expulsion or death. For example, in July 2023, the Centers for Disease Control and Prevention (CDC), a US-based national public health agency, reported a twofold increase in cyclosporiasis cases in Florida, from 254 cases in 2021 to 513 cases in 2022. Thus, the high prevalence of parasitic infections is fueling the growth of the anthelmintic drugs market.

Leading companies in the anthelmintic drugs market are focusing on developing innovative combination drugs to offer comprehensive protection against multiple parasites. Combination anthelmintic drugs are formulations that blend two or more anthelmintic agents to enhance efficacy against parasitic infections in both humans and animals. These drugs work synergistically to expand the range of activity, delay the onset of drug resistance, and address existing resistance in parasites. For instance, in January 2022, Zoetis Inc., a US-based animal health company, received approval from the U.S. Food and Drug Administration for Simparica Trio, a new label indication that allows it to prevent infections caused by Borrelia burgdorferi, which causes Lyme disease in dogs. Simparica Trio combines three active ingredients - sarolaner, moxidectin, and pyrantel - to provide broad protection against fleas, ticks, heartworms, roundworms, and hookworms.

In July 2023, Bayer AG, a Germany-based pharmaceutical and biotechnology company, partnered with the Swiss Tropical and Public Health Institute (Swiss TPH) to develop anthelmintic drug compounds for treating parasitic infections. This collaboration aims to assess the safety and efficacy of emodepside, a compound originally developed for veterinary use, for treating soil-transmitted helminths in humans. The goal is to provide a new treatment option and advance global health efforts by addressing a major public health challenge in developing regions. The Swiss Tropical and Public Health Institute (Swiss TPH) is a Switzerland-based research institute focused on global health and tropical diseases.

Major companies operating in the anthelmintic drugs market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Limited, Zoetis Inc., Hetero Labs Limited, Sun Pharmaceutical Industries Ltd., Galderma S.A., Cipla Inc., Ferring Pharmaceuticals Inc., Amneal Pharmaceuticals, Inc., Zydus Lifesciences Limited, Glenmark Pharmaceuticals Ltd., Mankind Pharma Ltd., Reese Pharmaceutical Company.

North America was the largest region in the anthelmintic drugs market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anthelmintic drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the anthelmintic drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Anthelmintic drugs are medications designed to treat infections caused by parasitic worms, or helminths. These drugs function by either killing the worms directly or disrupting their reproductive capabilities. They are commonly prescribed for conditions such as roundworm, tapeworm, and hookworm infections.

The primary classes of anthelmintic drugs include benzimidazoles, macrocyclic lactones, pyrazinoisoquinolones, tetrahydropyrimidines, and others. Benzimidazoles are a group of organic compounds featuring a benzene ring fused with an imidazole ring. They are utilized in various applications, including as pharmaceutical agents for treating parasitic infections and as key components in some synthetic materials. These drugs can be administered orally or via injection to treat a range of infections, including nematode, cestode, trematode, and mixed infections. They are distributed through multiple channels, such as hospitals and clinics, retail pharmacies, online pharmacies, and veterinary clinics and supply stores, and are used in both human and veterinary anthelmintics.

The anthelmintic drugs market research report is one of a series of new reports that provides anthelmintic drugs market statistics, including the anthelmintic drugs industry's global market size, regional shares, competitors with an anthelmintic drugs market share, detailed anthelmintic drugs market segments, market trends and opportunities, and any further data you may need to thrive in the anthelmintic drugs industry. This anthelmintic drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The anthelmintic drugs market consists of sales of albendazole, mebendazole, praziquantel, levamisole, piperazine, and ivermectin. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.